What is Theraclone Sciences?
Theraclone Sciences operates at the intersection of immunology and drug discovery, specializing in the rapid identification of rare human monoclonal antibodies. The company leverages a sophisticated screening technology designed to isolate potent therapeutic candidates capable of addressing complex infectious diseases and oncology indications. By maintaining a robust intellectual property portfolio, Theraclone has established strategic licensing partnerships with major industry players, including Gilead and OncoResponse, effectively validating its platform's utility in high-stakes pharmaceutical development. Its market position is defined by its ability to translate fundamental biological insights into actionable, clinical-grade therapeutic assets.
How much funding has Theraclone Sciences raised?
Theraclone Sciences has raised a total of $35.5M across 4 funding rounds:
Series A
$2M
Series B
$29M
Unspecified
$1.5M
Private Equity
$3.1M
Series A (2004): $2M, investors not publicly disclosed
Series B (2007): $29M led by Amgen Business Development, HealthCare Ventures, Alexandria Real Estate Equities, ARCH Venture Partners, Canaan Partners, and MPM Capital
Unspecified (2010): $1.5M supported by ARCH Venture Partners, MPM Capital, Alexandria Real Estate Equities, Canaan Partners, Healthcare Ventures, and Amgen Business Development
Private Equity (2015): $3.1M, investors not publicly disclosed
Key Investors in Theraclone Sciences
ARCH Venture Partners
ARCH Venture Partners is a leading early-stage venture capital firm that creates and invests in life sciences and advanced technology companies, often co-founding startups with scientists and entrepreneurs to commercialize innovations from universities, corporate R&D groups, and national laboratories.
Canaan Partners
Canaan is an early-stage venture capital firm that invests in technology and healthcare companies, backing founders from seed through growth stages in areas such as enterprise software, fintech, consumer, biopharma, and digital health.
MPM Capital
MPM BioImpact manages early-stage venture funds, private/public impact funds and a public equities fund, focusing on converting science into therapeutics to reach the patients that need them most.
What's next for Theraclone Sciences?
With the support of its institutional partners, Theraclone Sciences is well-positioned to deepen its pipeline development and expand its licensing footprint. The current funding context suggests a strategic pivot toward scaling its platform technology for broader oncology applications and refining its existing HIV-cure regimens. As the company continues to mature, the focus will likely shift toward optimizing clinical trial outcomes and maximizing the commercial potential of its licensed assets. Investors will be monitoring the firm's ability to maintain its competitive edge in antibody discovery while navigating the rigorous regulatory requirements inherent in the biotechnology sector.
See full Theraclone Sciences company page
